ACR 2022 Tweet by David Liew

I find this incredibly encouraging

SAPHYR subanalysis:
refractory PMR
sarilumab (w 14w PNL taper) vs placebo (w 52w taper)
?no Sx

Benefit kicks on after PNL taper stops, out to 52w
Reality in practice: bit more PNL prob gives excellent Sx outcomes

ABST1543 #ACR22 @RheumNow